SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Weidong Le, Pavani Sayana, Joseph Jankovic, Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?, Neurotherapeutics, 2014, 11, 1, 92

    CrossRef

  2. 2
    Tiago Zaminelli, Raísa Wendhausen Gradowski, Taysa Bervian Bassani, Janaína Kohl Barbiero, Ronise M. Santiago, Daniele Maria-Ferreira, Cristiane Hatsuko Baggio, Maria A. B. F. Vital, Antidepressant and Antioxidative Effect of Ibuprofen in the Rotenone Model of Parkinson’s Disease, Neurotoxicity Research, 2014,

    CrossRef

  3. 3
    Laura Abel, Simone Kutschki, Michael Turewicz, Martin Eisenacher, Jale Stoutjesdijk, Helmut E. Meyer, Dirk Woitalla, Caroline May, Autoimmune profiling with protein microarrays in clinical applications, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2014, 1844, 5, 977

    CrossRef

  4. 4
    Karunakar Kar, Irene Arduini, Kenneth W. Drombosky, Patrick C.A. van der Wel, Ronald Wetzel, d-Polyglutamine Amyloid Recruits l-Polyglutamine Monomers and Kills Cells, Journal of Molecular Biology, 2014, 426, 4, 816

    CrossRef

  5. 5
    Xiqi Liu, Rushing Shao, Meng Li, Guofeng Yang, Edaravone Protects Neurons in the Rat Substantia Nigra Against 6-Hydroxydopamine-Induced Oxidative Stress Damage, Cell Biochemistry and Biophysics, 2014,

    CrossRef

  6. 6
    Thomas Foltynie, Iciar Aviles-Olmos, Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic, Alzheimer's & Dementia, 2014, 10, 1, S38

    CrossRef

  7. 7
    Yuequn Li, Yonghua Li, Shuchao Pang, Wenhui Huang, Aimei Zhang, Robert G. Hawley, Bo Yan, Novel and functional ABCB1 gene variant in sporadic Parkinson’s disease, Neuroscience Letters, 2014, 566, 61

    CrossRef

  8. 8
    Weidong Le, Role of iron in UPS impairment model of Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, S158

    CrossRef

  9. 9
    David R. Shprecher, Kenneth F. Grossmann, Jonathan D. Tward, Sustained remission of Parkinson disease associated melanoma with immunotherapy, Parkinsonism & Related Disorders, 2014, 20, 9, 1027

    CrossRef

  10. 10
    F. L'Episcopo, C. Tirolo, S. Caniglia, N. Testa, M. C. Morale, M. F. Serapide, S. Pluchino, B. Marchetti, Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease, Journal of Molecular Cell Biology, 2014, 6, 1, 13

    CrossRef

  11. 11
    Kurt A Jellinger, The pathomechanisms underlying Parkinson's disease, Expert Review of Neurotherapeutics, 2014, 14, 2, 199

    CrossRef

  12. 12
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  13. 13
    K.A. Jellinger, Pathobiology of Human Disease, 2014,

    CrossRef

  14. 14
    Lilian Calderón-Garcidueñas, Maricela Franco-Lira, Antonieta Mora-Tiscareño, Humberto Medina-Cortina, Ricardo Torres-Jardón, Michael Kavanaugh, Early Alzheimer’s and Parkinson’s Disease Pathology in Urban Children: Friend versus Foe Responses—It Is Time to Face the Evidence, BioMed Research International, 2013, 2013, 1

    CrossRef

  15. 15
    Tom Foltynie, Joshua Kahan, Parkinson’s disease: an update on pathogenesis and treatment, Journal of Neurology, 2013, 260, 5, 1433

    CrossRef

  16. 16
    Günther Deuschl, Yves Agid, Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits, The Lancet Neurology, 2013, 12, 10, 1025

    CrossRef

  17. 17
    C. Warren Olanow, Jose A. Obeso, Fabrizio Stocchi, The Vatican Meeting on Neuroprotection for Parkinson's Disease, Movement Disorders, 2013, 28, 1
  18. 18
    Kurt A. Jellinger, Metal Related Neurodegenerative Disease, 2013,

    CrossRef